StockData
Myriad Genetics Inc logo

Myriad Genetics Inc (MYGN) stock

MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.53−0.01 (-0.18%)

Close on Nov 18, 2026Market cap $528.94MP/E –Yield –

Myriad Genetics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Myriad Genetics's revenue for the twelve months ending Jun 30, 2026 was $806.60M, down 3.2% year over year. For fiscal 2025 it was $824.50M, down 1.6% from the year before. Over ten years it grew 0.6% a year on average. The highest annual figure on record is $851.10M in fiscal 2019.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$824.50M-1.6%
FY2024Dec 31, 2024$837.60M+11.2%
FY2023Dec 31, 2023$753.20M+11.0%
FY2022Dec 31, 2022$678.40M+6.2%
FY2020Jun 30, 2020$638.60M-25.0%
FY2019Jun 30, 2019$851.10M+14.4%
FY2018Jun 30, 2018$743.70M+2.1%
FY2017Jun 30, 2017$728.70M-1.6%
FY2016Jun 30, 2016$740.50M+2.5%
FY2015Jun 30, 2015$722.50M-7.2%
FY2014Jun 30, 2014$778.20M+26.9%
FY2013Jun 30, 2013$613.20M+23.6%
FY2012Jun 30, 2012$496.01M+23.4%
FY2011Jun 30, 2011$402.08M+10.9%
FY2010Jun 30, 2010$362.65M+11.1%
FY2009Jun 30, 2009$326.53M–

Quarterly revenue

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026$190.70M-10.5%
Q1 FY2026CQ1 2026Mar 31, 2026$200.40M+2.3%
Q4 FY2025CQ4 2025Dec 31, 2025$209.80M-0.4%
Q3 FY2025CQ3 2025Sep 30, 2025$205.70M-3.6%
Q2 FY2025CQ2 2025Jun 30, 2025$213.10M+0.8%
Q1 FY2025CQ1 2025Mar 31, 2025$195.90M-3.1%
Q4 FY2024CQ4 2024Dec 31, 2024$210.60M+7.1%
Q3 FY2024CQ3 2024Sep 30, 2024$213.30M+11.2%
Q2 FY2024CQ2 2024Jun 30, 2024$211.50M+15.3%
Q1 FY2024CQ1 2024Mar 31, 2024$202.20M+11.6%
Q4 FY2023CQ4 2023Dec 31, 2023$196.60M+10.6%
Q3 FY2023CQ3 2023Sep 30, 2023$191.90M+22.7%
Q2 FY2023CQ2 2023Jun 30, 2023$183.50M+2.3%
Q1 FY2023CQ1 2023Mar 31, 2023$181.20M+9.9%
Q4 FY2022CQ4 2022Dec 31, 2022$177.80M+90.8%
Q3 FY2022CQ3 2022Sep 30, 2022$156.40M-4.6%
Q2 FY2022CQ2 2022Jun 30, 2022$179.30M-8.1%
Q1 FY2022CQ1 2022Mar 31, 2022$164.90M-11.5%
Q4 FY2020CQ2 2020Jun 30, 2020$93.20M-56.7%
Q3 FY2020CQ1 2020Mar 31, 2020$164.00M-24.3%
Q2 FY2020CQ4 2019Dec 31, 2019$195.10M-10.0%
Q1 FY2020CQ3 2019Sep 30, 2019$186.30M-7.9%
Q4 FY2019CQ2 2019Jun 30, 2019$215.40M+11.1%
Q3 FY2019CQ1 2019Mar 31, 2019$216.60M+18.3%
Q2 FY2019CQ4 2018Dec 31, 2018$216.80M+15.4%
Q1 FY2019CQ3 2018Sep 30, 2018$202.30M+13.1%
Q4 FY2018CQ2 2018Jun 30, 2018$193.90M-2.9%
Q3 FY2018CQ1 2018Mar 31, 2018$183.10M-6.0%
Q2 FY2018CQ4 2017Dec 31, 2017$187.90M-4.5%
Q1 FY2018CQ3 2017Sep 30, 2017$178.80M-0.1%
Q4 FY2017CQ2 2017Jun 30, 2017$199.60M+15.3%
Q3 FY2017CQ1 2017Mar 31, 2017$194.70M+2.2%
Q2 FY2017CQ4 2016Dec 31, 2016$196.70M+1.8%
Q1 FY2017CQ3 2016Sep 30, 2016$178.90M-2.5%
Q4 FY2016CQ2 2016Jun 30, 2016$173.10M-8.6%
Q3 FY2016CQ1 2016Mar 31, 2016$190.50M+5.8%
Q2 FY2016CQ4 2015Dec 31, 2015$193.30M–
Q1 FY2016CQ3 2015Sep 30, 2015$183.50M–
Q4 FY2015CQ2 2015Jun 30, 2015$189.30M–
Q3 FY2015CQ1 2015Mar 31, 2015$180.00M–

More Myriad Genetics figures

See a number that looks wrong?